Cable Hill Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Cable Hill Partners’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,500	Closed	-$20K	–	95
2020 Q1	$20K	Buy	+2,500	New	+$21.7K	0.01%	87
2019 Q4	–	Sell	-2,500	Closed	-$15K	–	121
2019 Q3	$15K	Buy	+2,500	New	+$20.2K	﹤0.01%	106
2019 Q2	–	Sell	-1,000	Closed	-$17K	–	747
2019 Q1	$17K	Hold	1,000	–	–	0.01%	405
2018 Q4	$11K	Buy	1,000 +250	+33%	+$5.06K	﹤0.01%	441
2018 Q3	$26K	Buy	750 +250	+50%	+$7.11K	0.01%	272
2018 Q2	$14K	Sell	500 -1,000	-67%	-$22.2K	0.01%	405
2018 Q1	$24K	Buy	+1,500	New	+$35.7K	0.01%	310

Other funds holding MRNS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Cable Hill Partners's MRNS Position: Q2 2020 in Review

Cable Hill Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2020, closing a stake of 2,500 shares — an estimated $20K sold.

Cable Hill Partners first reported a position in MRNS in Q1 2018 and held it in 7 quarters. The position peaked at $26K in Q3 2018. 94 funds tracked by Wall St. Rank hold MRNS as of Q2 2020.

Cable Hill Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
Cable Hill Partners sold 2,500 Marinus Pharmaceuticals, Inc shares in Q2 2020, an estimated $20K.
Cable Hill Partners first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 7 quarters.
Cable Hill Partners's Marinus Pharmaceuticals, Inc position peaked at $26K in Q3 2018.
94 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2020.

Based on Cable Hill Partners's 13F filing for Q2 2020, filed 13 Aug 2020.